Base de dados : MEDLINE
Pesquisa : D01.029.260.700.675.374.775.150 [Categoria DeCS]
Referências encontradas : 5544 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 555 ir para página                         

  1 / 5544 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29199987
[Au] Autor:Shornikov A; Tran H; Macias J; Halavaty AS; Minasov G; Anderson WF; Kuhn ML
[Ad] Endereço:Department of Chemistry and Biochemistry, San Francisco State University, USA.
[Ti] Título:Structure of the Bacillus anthracis dTDP-L-rhamnose-biosynthetic enzyme dTDP-4-dehydrorhamnose 3,5-epimerase (RfbC).
[So] Source:Acta Crystallogr F Struct Biol Commun;73(Pt 12):664-671, 2017 Dec 01.
[Is] ISSN:2053-230X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The exosporium layer of Bacillus anthracis spores is rich in L-rhamnose, a common bacterial cell-wall component, which often contributes to the virulence of pathogens by increasing their adherence and immune evasion. The biosynthetic pathway used to form the activated L-rhamnose donor dTDP-L-rhamnose consists of four enzymes (RfbA, RfbB, RfbC and RfbD) and is an attractive drug target because there are no homologs in mammals. It was found that co-purifying and screening RfbC (dTDP-6-deoxy-D-xylo-4-hexulose 3,5-epimerase) from B. anthracis in the presence of the other three B. anthracis enzymes of the biosynthetic pathway yielded crystals that were suitable for data collection. RfbC crystallized as a dimer and its structure was determined at 1.63 Šresolution. Two different ligands were bound in the protein structure: pyrophosphate in the active site of one monomer and dTDP in the other monomer. A structural comparison with RfbC homologs showed that the key active-site residues are conserved across kingdoms.
[Mh] Termos MeSH primário: Bacillus anthracis/enzimologia
Proteínas de Bactérias/química
Carboidratos Epimerases/química
[Mh] Termos MeSH secundário: Proteínas de Bactérias/metabolismo
Carboidratos Epimerases/metabolismo
Domínio Catalítico
Cristalografia por Raios X
Difosfatos/química
Difosfatos/metabolismo
Modelos Moleculares
Conformação Proteica
Homologia Estrutural de Proteína
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Diphosphates); 4E862E7GRQ (diphosphoric acid); EC 5.1.3.- (Carbohydrate Epimerases); EC 5.1.3.13 (dTDP-4-ketorhamnose 3,5-epimerase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.1107/S2053230X17015849


  2 / 5544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28468891
[Au] Autor:Monnard A; Moretti D; Zeder C; Steingötter A; Zimmermann MB
[Ad] Endereço:Department of Health Sciences and Technology, Laboratory of Human Nutrition, ETH Zürich, Zurich, Switzerland; and.
[Ti] Título:The effect of lipids, a lipid-rich ready-to-use therapeutic food, or a phytase on iron absorption from maize-based meals fortified with micronutrient powders.
[So] Source:Am J Clin Nutr;105(6):1521-1527, 2017 Jun.
[Is] ISSN:1938-3207
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Ready-to-use-therapeutic foods (RUTFs) high in lipid, protein, and iron are used to treat malnutrition. Lipids increase gastric residence time, which could increase iron absorption, particularly from poorly soluble iron compounds and in combination with phytase. The objectives were to ) assess the effect on iron absorption of a lipid emulsion given 20 min before or together with an iron-fortified maize meal and ) assess iron absorption from a micronutrient powder (MNP) given with a nutrient-dense RUTF and/or a microbial phytase. A total of 41 women participated in 3 studies. They consumed a maize meal fortified with isotopically labeled ferrous sulfate (FeSO ; study 1) or ferric pyrophosphate (FePP; study 2). In studies 1 and 2, a lipid emulsion was given with or 20 min before the meal. In study 3, with the use of a 2 × 2 factorial design, subjects consumed a maize meal fortified with an MNP containing labeled FeSO (MNP) given with an RUTF (MNP+RUTF), with a phytase (MNP+phytase), or both (MNP+RUTF+phytase). Iron absorption was assessed by isotope incorporation in erythrocytes 14 d after the test meals. The lipid emulsion given either before or with the meal significantly increased iron absorption from FePP by 2.55-fold (95% CI: 1.48-, 4.37-fold; = 0.001) but not from FeSO There was a trend to increase iron absorption with the MNP+RUTF meal, which did not reach significance (1.21-fold; 95% CI: 0.92-, 1.61-fold; = 0.060). The addition of phytase to MNP and MNP+RUTF significantly increased iron absorption by 1.85-fold (95% CI: 1.49-, 2.29-fold; < 0.001), with no interaction between phytase and RUTF. In iron-fortified maize-based meals, the addition of lipids more than doubles iron absorption from FePP. Our results suggest the possibility of an enhancing effect on iron absorption of lipid-rich RUTFs, but more research is needed to determine this. This trial was registered at clinicaltrials.gov as NCT01991626.
[Mh] Termos MeSH primário: 6-Fitase/farmacologia
Alimentos Fortificados
Absorção Intestinal/efeitos dos fármacos
Ferro na Dieta/sangue
Ferro/sangue
Lipídeos/farmacologia
Micronutrientes/sangue
[Mh] Termos MeSH secundário: Adulto
Suplementos Nutricionais
Difosfatos/sangue
Eritrócitos/metabolismo
Feminino
Ferritinas/sangue
Seres Humanos
Refeições
Pós
Adulto Jovem
Zea mays
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Diphosphates); 0 (Iron, Dietary); 0 (Lipids); 0 (Micronutrients); 0 (Powders); 9007-73-2 (Ferritins); E1UOL152H7 (Iron); EC 3.1.3.26 (6-Phytase); QK8899250F (ferric pyrophosphate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180121
[Lr] Data última revisão:
180121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170505
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.3945/ajcn.116.142976


  3 / 5544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27777304
[Au] Autor:Li A; Gong S; Johnson KA
[Ad] Endereço:From the University of Texas at Austin, Institute for Cell and Molecular Biology, Department of Molecular Biosciences, Austin, Texas 78712.
[Ti] Título:Rate-limiting Pyrophosphate Release by HIV Reverse Transcriptase Improves Fidelity.
[So] Source:J Biol Chem;291(51):26554-26565, 2016 Dec 16.
[Is] ISSN:1083-351X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Previous measurements of the rates of polymerization and pyrophosphate release with DNA templates showed that pyrophosphate (PP ) dissociation was fast after nucleotide incorporation so that it did not contribute to enzyme specificity (k /K ). Here, kinetic parameters governing nucleotide incorporation and PP release were determined using an RNA template. Compared with a DNA template of the same sequence, the rate of chemistry increased by up to 10-fold (250 versus 24 s ), whereas the rate of PP release decreased to approximately 58 s so that PP release became the rate-limiting step. During processive nucleotide incorporation, the first nucleotide (TTP) was incorporated at a fast rate (152 s ), whereas the rates of incorporation of remaining nucleotides (CGTCG) were much slower with an average rate of 24 s , suggesting that sequential incorporation events were limited by the relatively slow PP release step. The accompanying paper shows that slow PP release allows polymerization and RNase H to occur at comparable rates. Although PP release is the rate-determining step, it is not the specificity-determining step for correct incorporation based on our current estimates of the rate of reversal of the chemistry step (3 s ). In contrast, during misincorporation, PP release became extremely slow, which we estimated to be ∼0.002 s These studies establish the mechanistic basis for DNA polymerase fidelity during reverse transcription and provide a free energy profile. We correct previous underestimates of discrimination by including the slow PP release step. Our current estimate of 2.4 × 10 is >20-fold greater than estimated previously.
[Mh] Termos MeSH primário: Difosfatos/química
Transcriptase Reversa do HIV/química
HIV-1/enzimologia
Ribonuclease H/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Diphosphates); 4E862E7GRQ (diphosphoric acid); EC 2.7.7.- (reverse transcriptase, Human immunodeficiency virus 1); EC 2.7.7.49 (HIV Reverse Transcriptase); EC 3.1.26.4 (Ribonuclease H)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171216
[Lr] Data última revisão:
171216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  4 / 5544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28723890
[Au] Autor:Kemp BE; Oakhill JS
[Ad] Endereço:St Vincent's Institute of Medical Research, Fitzroy, Victoria 3065, Australia.
[Ti] Título:Metabolism: Energy sensing through a sugar diphosphate.
[So] Source:Nature;548(7665):36-37, 2017 08 03.
[Is] ISSN:1476-4687
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Carboidratos
Difosfatos
[Mh] Termos MeSH secundário: Metabolismo dos Carboidratos
Metabolismo Energético
Seres Humanos
[Pt] Tipo de publicação:NEWS; COMMENT
[Nm] Nome de substância:
0 (Carbohydrates); 0 (Diphosphates)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE
[do] DOI:10.1038/nature23099


  5 / 5544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28708284
[Au] Autor:Peipp M; Wesch D; Oberg HH; Lutz S; Muskulus A; van de Winkel JGJ; Parren PWHI; Burger R; Humpe A; Kabelitz D; Gramatzki M; Kellner C
[Ad] Endereço:Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Christian-Albrechts-University of Kiel, Kiel, Germany.
[Ti] Título:CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.
[So] Source:Scand J Immunol;86(4):196-206, 2017 Oct.
[Is] ISSN:1365-3083
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Human γδ T cells are innate-like T cells which are able to kill a broad range of tumour cells and thus may have potential for cancer immunotherapy. The activating receptor natural killer group 2 member D (NKG2D) plays a key role in regulating immune responses driven by γδ T cells. Here, we explored whether recombinant immunoligands consisting of a CD20 single-chain fragment variable (scFv) linked to a NKG2D ligand, either MHC class I chain-related protein A (MICA) or UL16 binding protein 2 (ULBP2), could be employed to engage γδ T cells for tumour cell killing. The two immunoligands, designated MICA:7D8 and ULBP2:7D8, respectively, enhanced cytotoxicity of ex vivo-expanded γδ T cells against CD20-positive lymphoma cells. Both Vδ1 and Vδ2 γδ T cells were triggered by MICA:7D8 or ULBP2:7D8. Killing of CD20-negative tumour cells was not induced by the immunoligands, indicating their antigen specificity. MICA:7D8 and ULBP2:7D8 acted in a dose-dependent manner and induced cytotoxicity at nanomolar concentrations. Importantly, chronic lymphocytic leukaemia (CLL) cells isolated from patients were sensitized by the two immunoligands for γδ T cell cytotoxicity. In a combination approach, the immunoligands were combined with bromohydrin pyrophosphate (BrHPP), an agonist for Vδ2 γδ T cells, which further enhanced the efficacy in target cell killing. Thus, employing tumour-directed recombinant immunoligands which engage NKG2D may represent an attractive strategy to enhance antitumour cytotoxicity of γδ T cells.
[Mh] Termos MeSH primário: Antígenos CD20/metabolismo
Citotoxicidade Imunológica
Imunoterapia/métodos
Linfoma/terapia
Subfamília K de Receptores Semelhantes a Lectina de Células NK/metabolismo
Anticorpos de Cadeia Única/uso terapêutico
Linfócitos T/fisiologia
[Mh] Termos MeSH secundário: Antígenos CD20/imunologia
Difosfatos/uso terapêutico
Quimioterapia Combinada
Proteínas Ligadas por GPI/genética
Antígenos de Histocompatibilidade Classe I/genética
Seres Humanos
Imunização
Peptídeos e Proteínas de Sinalização Intercelular/genética
Linfoma/imunologia
Receptores de Antígenos de Linfócitos T gama-delta/metabolismo
Anticorpos de Cadeia Única/genética
Células Tumorais Cultivadas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD20); 0 (Diphosphates); 0 (GPI-Linked Proteins); 0 (Histocompatibility Antigens Class I); 0 (Intercellular Signaling Peptides and Proteins); 0 (KLRK1 protein, human); 0 (MHC class I-related chain A); 0 (NK Cell Lectin-Like Receptor Subfamily K); 0 (Receptors, Antigen, T-Cell, gamma-delta); 0 (Single-Chain Antibodies); 0 (ULBP2 protein, human); 0 (bromohydrin pyrophosphate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170715
[St] Status:MEDLINE
[do] DOI:10.1111/sji.12581


  6 / 5544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28704395
[Au] Autor:Caballero D; Li Y; Fetene J; Ponsetto J; Chen A; Zhu C; Braddock DT; Bergwitz C
[Ad] Endereço:Department of Medicine, Section Endocrinology, Yale University School of Medicine, New Haven, CT, United States of America.
[Ti] Título:Intraperitoneal pyrophosphate treatment reduces renal calcifications in Npt2a null mice.
[So] Source:PLoS One;12(7):e0180098, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mutations in the proximal tubular sodium-dependent phosphate co-transporters NPT2a and NPT2c have been reported in patients with renal stone disease and nephrocalcinosis, however the relative contribution of genotype, dietary calcium and phosphate, and modifiers of mineralization such as pyrophosphate (PPi) to the formation of renal mineral deposits is unclear. In the present study, we used Npt2a-/- mice to model the renal calcifications observed in these disorders. We observed elevated urinary excretion of PPi in Npt2a-/- mice when compared to WT mice. Presence of two hypomorphic Extracellular nucleotide pyrophosphatase phosphodiesterase 1 (Enpp1asj/asj) alleles decreased urine PPi and worsened renal calcifications in Npt2a-/- mice. These studies suggest that PPi is a thus far unrecognized factor protecting Npt2a-/- mice from the development of renal mineral deposits. Consistent with this conclusion, we next showed that renal calcifications in these mice can be reduced by intraperitoneal administration of sodium pyrophosphate. If confirmed in humans, urine PPi could therefore be of interest for developing new strategies to prevent the nephrocalcinosis and nephrolithiasis seen in phosphaturic disorders.
[Mh] Termos MeSH primário: Difosfatos/administração & dosagem
Difosfatos/urina
Cálculos Renais/tratamento farmacológico
Diester Fosfórico Hidrolases/genética
Pirofosfatases/genética
Proteínas Cotransportadoras de Sódio-Fosfato Tipo IIa/genética
[Mh] Termos MeSH secundário: Animais
Difosfatos/uso terapêutico
Modelos Animais de Doenças
Feminino
Seres Humanos
Injeções Intraperitoneais
Cálculos Renais/genética
Cálculos Renais/urina
Masculino
Camundongos
Camundongos Knockout
Mutação
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Diphosphates); 0 (Slc34a1 protein, mouse); 0 (Sodium-Phosphate Cotransporter Proteins, Type IIa); 4E862E7GRQ (diphosphoric acid); EC 3.1.4.- (Phosphoric Diester Hydrolases); EC 3.1.4.1 (ectonucleotide pyrophosphatase phosphodiesterase 1); EC 3.6.1.- (Pyrophosphatases); O352864B8Z (sodium pyrophosphate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170921
[Lr] Data última revisão:
170921
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170714
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0180098


  7 / 5544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28559059
[Au] Autor:Elumalai N; Natarajan K; Berg T
[Ad] Endereço:Institute of Organic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany.
[Ti] Título:Halogen-substituted catechol bisphosphates are potent and selective inhibitors of the transcription factor STAT5b.
[So] Source:Bioorg Med Chem;25(14):3871-3882, 2017 Jul 15.
[Is] ISSN:1464-3391
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The transcription factor STAT5b is an antitumor target. Recently, we presented the small molecules Stafib-1 and Stafib-2 as potent, selective inhibitors of the STAT5b SH2 domain. Here we report that halogen substitutions on the terminal phenyl ring of Stafib-1 and a close derivative are tolerated and specificity over the STAT5a SH2 domain is maintained, albeit with a slight reduction in activity. Our data demonstrate that the synthetic methodology used for generating Stafib-1 and Stafib-2 can be utilized to synthesize a small library of halogen-substituted derivatives, and extend the panel of catechol bisphosphate-based submicromolar and selective STAT5b inhibitors.
[Mh] Termos MeSH primário: Catecóis/química
Difosfatos/química
Halogênios/química
Fator de Transcrição STAT5/antagonistas & inibidores
[Mh] Termos MeSH secundário: Sítios de Ligação
Catecóis/síntese química
Catecóis/metabolismo
Seres Humanos
Concentração Inibidora 50
Simulação de Acoplamento Molecular
Estrutura Terciária de Proteína
Fator de Transcrição STAT5/metabolismo
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Catechols); 0 (Diphosphates); 0 (Halogens); 0 (STAT5 Transcription Factor)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170601
[St] Status:MEDLINE


  8 / 5544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28531840
[Au] Autor:Fischbacher A; von Sonntag C; Schmidt TC
[Ad] Endereço:Instrumental Analytical Chemistry, University of Duisburg-Essen, Universitätsstraße 5, 45141 Essen, Germany.
[Ti] Título:Hydroxyl radical yields in the Fenton process under various pH, ligand concentrations and hydrogen peroxide/Fe(II) ratios.
[So] Source:Chemosphere;182:738-744, 2017 Sep.
[Is] ISSN:1879-1298
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The Fenton process, one of several advanced oxidation processes, describes the reaction of Fe(II) with hydrogen peroxide. Fe(II) is oxidized to Fe(III) that reacts with hydrogen peroxide to Fe(II) and again initiates the Fenton reaction. In the course of the reactions reactive species, e.g. hydroxyl radicals, are formed. Conditions such as pH, ligand concentrations and the hydrogen peroxide/Fe(II) ratio may influence the OH radical yield. It could be shown that at pH < 2.7 and >3.5 the OH radical yield decreases significantly. Two ligands were investigated, pyrophosphate and sulfate. It was found that pyrophosphate forms a complex with Fe(III) that does not react with hydrogen peroxide and thus, the Fenton reaction is terminated and the OH radical yields do not further increase. The influence of sulfate is not as strong as that of pyrophosphate. The OH radical yield is decreased when sulfate is added but even at higher concentrations the Fenton reaction is not terminated.
[Mh] Termos MeSH primário: Difosfatos/química
Compostos Ferrosos/química
Peróxido de Hidrogênio/química
Radical Hidroxila/síntese química
Ferro/química
Sulfatos/química
[Mh] Termos MeSH secundário: Concentração de Íons de Hidrogênio
Ligantes
Oxirredução
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Diphosphates); 0 (Ferrous Compounds); 0 (Ligands); 0 (Sulfates); 3352-57-6 (Hydroxyl Radical); 4E862E7GRQ (diphosphoric acid); BBX060AN9V (Hydrogen Peroxide); E1UOL152H7 (Iron)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170523
[St] Status:MEDLINE


  9 / 5544 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28416300
[Au] Autor:Pomozi V; Brampton C; van de Wetering K; Zoll J; Calio B; Pham K; Owens JB; Marh J; Moisyadi S; Váradi A; Martin L; Bauer C; Erdmann J; Aherrahrou Z; Le Saux O
[Ad] Endereço:Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii.
[Ti] Título:Pyrophosphate Supplementation Prevents Chronic and Acute Calcification in ABCC6-Deficient Mice.
[So] Source:Am J Pathol;187(6):1258-1272, 2017 Jun.
[Is] ISSN:1525-2191
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Soft tissue calcification occurs in several common acquired pathologies, such as diabetes and hypercholesterolemia, or can result from genetic disorders. ABCC6, a transmembrane transporter primarily expressed in liver and kidneys, initiates a molecular pathway inhibiting ectopic calcification. ABCC6 facilitates the cellular efflux of ATP, which is rapidly converted into pyrophosphate (PPi), a major calcification inhibitor. Heritable mutations in ABCC6 underlie the incurable calcification disorder pseudoxanthoma elasticum and some cases of generalized arterial calcification of infancy. Herein, we determined that the administration of PPi and the bisphosphonate etidronate to Abcc6 mice fully inhibited the acute dystrophic cardiac calcification phenotype, whereas alendronate had no significant effect. We also found that daily injection of PPi to Abcc6 mice over several months prevented the development of pseudoxanthoma elasticum-like spontaneous calcification, but failed to reverse already established lesions. Furthermore, we found that the expression of low amounts of the human ABCC6 in liver of transgenic Abcc6 mice, resulting in only a 27% increase in plasma PPi levels, led to a major reduction in acute and chronic calcification phenotypes. This proof-of-concept study shows that the development of both acute and chronic calcification associated with ABCC6 deficiency can be prevented by compensating PPi deficits, even partially. Our work indicates that PPi substitution represents a promising strategy to treat ABCC6-dependent calcification disorders.
[Mh] Termos MeSH primário: Transportadores de Cassetes de Ligação de ATP/fisiologia
Calcinose/prevenção & controle
Difosfatos/uso terapêutico
Pseudoxantoma Elástico/prevenção & controle
[Mh] Termos MeSH secundário: Transportadores de Cassetes de Ligação de ATP/deficiência
Transportadores de Cassetes de Ligação de ATP/genética
Doença Aguda
Animais
Calcinose/metabolismo
Calcinose/patologia
Doença Crônica
Difosfatos/administração & dosagem
Difosfatos/metabolismo
Modelos Animais de Doenças
Relação Dose-Resposta a Droga
Avaliação Pré-Clínica de Medicamentos/métodos
Ácido Etidrônico/uso terapêutico
Feminino
Fígado/metabolismo
Masculino
Camundongos Endogâmicos C57BL
Camundongos Knockout
Proteínas Associadas à Resistência a Múltiplos Medicamentos/genética
Proteínas Associadas à Resistência a Múltiplos Medicamentos/metabolismo
Fenótipo
Pseudoxantoma Elástico/metabolismo
Pseudoxantoma Elástico/patologia
Transgenes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ABCC6 protein, human); 0 (Abcc6 protein, mouse); 0 (Diphosphates); 0 (Multidrug Resistance-Associated Proteins); 4E862E7GRQ (diphosphoric acid); M2F465ROXU (Etidronic Acid)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170831
[Lr] Data última revisão:
170831
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170419
[St] Status:MEDLINE


  10 / 5544 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28415544
[Au] Autor:Anastasiou AD; Strafford S; Posada-Estefan O; Thomson CL; Hussain SA; Edwards TJ; Malinowski M; Hondow N; Metzger NK; Brown CTA; Routledge MN; Brown AP; Duggal MS; Jha A
[Ad] Endereço:School of Chemical and Process Engineering, University of Leeds, Leeds LS2 9JT, UK. Electronic address: a.anastasiou@leeds.ac.uk.
[Ti] Título:ß-pyrophosphate: A potential biomaterial for dental applications.
[So] Source:Mater Sci Eng C Mater Biol Appl;75:885-894, 2017 Jun 01.
[Is] ISSN:1873-0191
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Tooth hypersensitivity is a growing problem affecting both the young and ageing population worldwide. Since an effective and permanent solution is not yet available, we propose a new methodology for the restoration of dental enamel using femtosecond lasers and novel calcium phosphate biomaterials. During this procedure the irradiated mineral transforms into a densified layer of acid resistant iron doped ß-pyrophosphate, bonded with the surface of eroded enamel. Our aim therefore is to evaluate this densified mineral as a potential replacement material for dental hard tissue. To this end, we have tested the hardness of ß-pyrophosphate pellets (sintered at 1000°C) and its mineral precursor (brushite), the wear rate during simulated tooth-brushing trials and the cytocompatibility of these minerals in powder form. It was found that the hardness of the ß-pyrophosphate pellets is comparable with that of dental enamel and significantly higher than dentine while, the brushing trials prove that the wear rate of ß-pyrophosphate is much slower than that of natural enamel. Finally, cytotoxicity and genotoxicity tests suggest that iron doped ß-pyrophosphate is cytocompatible and therefore could be used in dental applications. Taken together and with the previously reported results on laser irradiation of these materials we conclude that iron doped ß-pyrophosphate may be a promising material for restoring acid eroded and worn enamel.
[Mh] Termos MeSH primário: Materiais Biocompatíveis/química
Fosfatos de Cálcio/química
Esmalte Dentário/química
[Mh] Termos MeSH secundário: Animais
Bovinos
Difosfatos/química
Microscopia Eletrônica de Varredura
Difração de Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biocompatible Materials); 0 (Calcium Phosphates); 0 (Diphosphates); 4E862E7GRQ (diphosphoric acid); 97Z1WI3NDX (calcium phosphate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170419
[St] Status:MEDLINE



página 1 de 555 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde